This website uses cookies.

By clicking the "Accept" button or continuing to browse our site, you agree to first-party and session-only cookies being stored on your device to enhance site navigation and analyze site performance and traffic. For more information on our use of cookies, please see our Privacy Policy.

  1. Home
  2. Journals
  3. American Economic Journal: Economic Policy
  4. November 2010
  5. The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation

The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation

Download Full Text PDF

Abstract

This paper analyzes the relationship between postmarketing promotional activity and reporting of adverse drug reactions (ADRs) by modeling the interaction between a regulator (the FDA) and a pharmaceutical firm. Promotion-driven market expansions enhance profitability yet may involve the risk of inappropriate drug prescriptions, leading to regulatory actions against the firm. We empirically test the relationship between drug promotion and reporting of ADRs using an innovative combination of commercial data on pharmaceutical promotion and FDA data on regulatory interventions and ADRs. We provide some evidence that increased levels of promotion and advertising lead to increased reporting of ADRs for certain conditions. (JEL L51, L65, M31, M37)

Citation

David, Guy, Sara Markowitz, and Seth Richards-Shubik. 2010. "The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation." American Economic Journal: Economic Policy, 2 (4): 1-25. DOI: 10.1257/pol.2.4.1

Additional Materials

JEL Classification

  • L51 Economics of Regulation
  • L65 Chemicals; Rubber; Drugs; Biotechnology
  • M31 Marketing
  • M37 Advertising
There are no comments for this article.
Login to Comment